Ventric Health Resources Hub
Your destination for evidence-driven heart failure decision support.
Our resources hub is designed to help you make informed decisions with evidence organized around real-world impact. You’ll discover peer-reviewed research, clinical validation, workflow insights and economic evidence around the questions decision-makers face.
Filter by topic or content type to quickly find the information most relevant to your role, setting and priorities. For additional information about the Vivio System, browse our FAQs.
Seeking Peer-Reviewed Evidence?
Vivio’s clinical validity is established by landmark peer-reviewed studies and recognized by leading clinical media. See Vivio validated in literature >
JACC Noninvasive Screening for Elevated LVEDP Study
This primary-care screening study found nearly 40% of high-risk outpatients had elevated LVEDP detected non-invasively, many without a prior heart-failure diagnosis. The results demonstrate how objective physiologic assessment can be integrated into routine workflows to uncover hidden cardiac risk and support earlier referral, monitoring, and escalation decisions.
Innovating Heart Failure: Start-Ups Harness Natural Pathways
In the March 2026 edition of MedTech Strategist, next-generation start-ups are examined for tackling heart failure as a systemic condition by harnessing natural physiological pathways. Ventric Health is featured prominently for its FDA-cleared Vivio device, which brings noninvasive early heart failure detection to primary care — identifying elevated filling pressures in both HFrEF and HFpEF patients before symptoms fully emerge.
JAHA Multicenter Validation Study (2025)
Screening patients for elevated LVEDP using a novel noninvasive brachial cuff-ECG system validated a scalable method for detecting a key physiologic marker of heart failure often missed in routine care. The study shows filling pressures can be identified accurately at the point of care, supporting earlier intervention and reducing diagnostic delay across primary and community settings.
HFSA Prevention Abstract (2025)
Presented at HFSA, this analysis shows non-invasive sensing can detect early volume overload in Stage A patients before symptoms develop. The findings support prevention-focused care models that identify physiologic risk sooner. For value-based care leaders, the evidence reinforces opportunities to intervene earlier and reduce downstream clinical deterioration and cost burden.
Multicenter Validation: Vivio System for Non-Invasive LVEDP Detection
Findings presented at the 2023 American Heart Association Scientific Symposium highlighted a pivotal study demonstrating validation of a noninvasive brachial cuff-ECG system for estimation of elevated left ventricular end diastolic pressure (LVEDP). The study provides the physician community with evidence that the Vivio® device plays an important role in improving the ability to accurately and non-invasively detect elevated LVEDP.
Ventric Health Receives FDA 510(k) Clearance for Vivio
Ventric Health announced that its medical device, the Vivio System™, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Vivio is a non-invasive medical device developed to quickly deliver the cardiovascular insights value-based care organizations need to reduce costs and improve patient lives.
